EXEL loses 5% after Oppenheimer downgrades its rating to Perform from Outperform on concerns about the potential differentiation of pipeline candidate zanzalintinib versus cabozantinib following the ...

Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason Gerberry from ...

Fintel reports that on January 27, 2025, Morgan Stanley upgraded their outlook for Exelixis (NasdaqGS:EXEL) from Equal-Weight to Overweight. Analyst Price Forecast Suggests 4.10% Upside As of December ...

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Exelixis (EXEL – Research Report), with a price target of ...

JMP Securities maintained a positive stance on Exelixis (NASDAQ:EXEL) stock, reiterating a Market Outperform rating with a ...

Park Avenue Securities LLC acquired a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and ...

Median duration of therapy was 20.5 months for the combination and 16.4 months with single-agent nivolumab. Median number of ...

Southern Missouri Bancorp Inc (SMBC) is expected to report $1.26 for 2Q. Super Micro Computer Inc (SMCI) is expected to report for 2Q. Transcat Inc (TRNS) is expected to report $0.33 for 3Q. Virginia ...

Several drugmakers shared new clinical data at this year’s ASCO GI Symposium in San Francisco, and Endpoints News has rounded ...